Analyst Round-Up Arena Pharma (ARNA): Downgraded at Barclays, Oppenheimer, Defended by Piper Jaffray
Tweet Send to a Friend
With shares of Arena Pharma (Nasdaq: ARNA) down about 38% today amid concerning FDA briefing documents, a few analyst downgrades ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
